Cleo
-30%
est. 2Y upside i
Rank
#2965
Sector
Digital Health
Est. Liquidity
~3Y
Data Quality
Data: LowThis analysis is highly uncertain due to missing financial data.
Last updated: July 3, 2026
Uncertain due to missing data. If Cleo has grown revenue significantly (e.g., >40% YoY) and IPO window opens, equity could appreciate strongly. Notable customers (Salesforce, PepsiCo) and low capital intensity support potential.
Cannot compute precisely due to missing revenue and valuation. Stale Series C from 2021 suggests flat or moderate growth; high incumbent threat from Maven and Carrot limits upside. Expect modest dilution and preference overhang.
If company fails to raise capital or loses competitive battle, common equity is worthless. Total funding of $86.9M creates large preference stack; any exit below that wipes out common.
Preference Stack Risk
highFunding Intensity
0%Total funding of $86.9M likely exceeds or is a large portion of current valuation, leading to significant preference overhang for common stock.
Dilution Risk
highNo funding in 5+ years suggests a raise is imminent, likely at a down or flat round, diluting existing holders.
Secondary Liquidity
noneNo secondary trading reported; liquidity for employee equity is uncertain.
Other — 8 roles
- Account Executive · Remote -USA
- Customer Success Manager · Remote - US
- Director of Customer Growth & Integrated Campaigns · Chicago, Illinois
- +5 more →
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on Cleo's data — designed to show you've done your homework.
- 1
“What is Cleo's current annual recurring revenue (ARR) and growth rate?”
- 2
“How does Cleo differentiate from Maven Clinic and Carrot Fertility in terms of employer adoption?”
- 3
“What is the expected timeline for an IPO or acquisition, and what is the current common stock valuation?”
Community
Valuation Sentiment
Our model estimates -30% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.